Search PubMed⌕ Search

Biomedical subjects

W J Brockway

Publications and source records attributed to W J Brockway.

16 recordsLinked to original sources

Production of alpha 1-proteinase inhibitor (human).

A method for large scale isolation of alpha 1-proteinase inhibitor (alpha 1-PI) is described. This method employs waste Cohn Fraction IV-1 as the starting material and involves fractional precipitation with polyethylene glycol followed by ion exchange chromatography on diethylaminoethanol (DEAE)-Sepharose. The process also incorporates a ten hour, at 60 degrees C, heat-treatment step to reduce or eliminate the risk of transmission of viral disease. The final product, having a purity of approximately 60%, is freeze-dried. This preparation behaves almost identically to the alpha 1-PI in plasma and is suitable for replacement therapy in hereditary emphysema.

Chromatography, High Pressure Liquid↗

Characterisation and virus safety of alpha 1-proteinase inhibitor.

Alpha 1-proteinase inhibitor (alpha 1-PI) concentrate is prepared from Cohn fraction IV-1 by precipitation and ion-exchange chromatography. A pasteurisation step (60 degrees, 10 hours) is introduced in this process with the aim at lowering the risk of transmitting infectious agents. Characterisation studies of alpha 1-PI with electrophoretic, immunologic and chemical methods demonstrated that the final product behaved the same as alpha 1-PI in human plasma. In particular, neo-antigens were not detected and the association rate constant of the final product was shown to be very similar to the constant published in the literature. The inactivation kinetic studies of eight different viruses showed that the heat treatment had a profound effect on their inactivation, the retroviruses such as HIV and Visna becoming undetectable after less than one hour of heat treatment.

Drug Contamination↗

Preparation and properties of alpha 1-proteinase inhibitor concentrate from human plasma.

Alpha 1-proteinase inhibitor (alpha 1-PI) has been prepared as a concentrate in quantities large enough for clinical testing of its safety and efficacy in the treatment of emphysema and other disorders. The alpha 1-PI was purified from Cohn fraction IV-1 paste by polyethylene glycol precipitation and DEAE-Sepharose chromatography. The methods used in the purification are gentle and the resulting product behaves almost identically to the alpha 1-PI from plasma. The protein has been heat treated (60 degrees C, 10 h) to lower the risk of transmission of plasma-borne diseases. This resulted in some aggregation of the protein, but did not cause the generation of new antigenic sites. Half-life studies in animals showed that the protein behaved normally (catabolic t1/2 of 68 h).

Blood Proteins↗

Purification of porcine and human ristocetin-Willebrand factor.

A plasmatic component required for the ristocetin-induced aggregation of platelets has been purified from normal human and porcine plasma by gel filtration (4% agarose) and anion-exchange chromatography (DEAE cellulose). No factor VIII coagulant activity was found associated with the purified human or porcine component. Urea sodium dodecylsulfate electrophoretic analysis of the purified component of both species indicated that the apparent molecular weight with intact disulfides is in excess of 500,000; after disulfide reduction with 2-mercaptoethanol, single components with an apparent subunit molecular weight of 230,000 were observed. Purified porcine ristocetin-Willebrand factor (RWF) co-sedimented in sucrose gradients with the factor present in normal plasma. Amino acid analysis of both human and porcine RWF indicated that all normal amino acids are present, whereas amino sugars were undetected. However, lipid analysis indicated 1% to 2% lipids present, including monoglycerides, di- and tri-glycerides, cholesterol, cholesterol esters, some free fatty acids, and a trace of phospholipid. A single line of identity was observed between normal human plasma and purified human RWF when immunodiffusion plates were run with purified rabbit anti-human RWF immunoglobulins. Antisera raised against human and porcine RWF's do not inhibit the factor VIII coagulant activity of the homologous plasma, nor is "spontaneously occurring" human factor VIII inhibitor neutralized by the isolated material of either species.

Amino Acids↗

Streptokinase.

Explore the source record for details and available documents.

Amino Acids↗

Evaluation of ristocetin-Willebrand factor assay and ristocetin-induced platelet aggregation.

Normal subjects, patients with various bleeding disorders, and patients with von Willebrand's disease were studied. All patients with von Willebrand's disease had decreased levels of ristocetin-Willebrand factor (range, 0 to 41%) as compared with all other subjects (range, 79 to 202%). Ristocetin-induced platelet aggregation of platelet-rich plasma was abnormal in all patients with von Willebrand's disease tested, and it was possible to correct this abnormal response by addition of normal platelet-poor plasma. Abnormal ristocetin-induced platelet aggregation was seen in patients with intrinsic platelet disorders or, on some occasions, in normal patients who had ingested aspirin. Ristocetin-induced platelet aggregation is not diagnostic, but it may be useful as a simple screening test for patients with possible von Willebrand's disease. In conjunction with other tests, the assay for ristocetin-Willebrand factor will be useful in diagnosis and evaluation of these patients.

Anticoagulants↗